Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome

Atherosclerosis

Volumn 181, Issue 2, 2005, Pages 321-327

  Nakamura, Takamitsu ^a   Takano, Hajime ^a   Umetani, Ken ^a   Kawabata, Ken Ichi ^a   Obata, Jyun Ei ^a   Kitta, Yoshinobu ^a   Kodama, Yasushi ^a   Mende, Akira ^a   Ichigi, Yoshihide ^a   Fujioka, Daisuke ^a   Saito, Yukio ^a   Kugiyama, Kiyotaka ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Atherosclerosis; Coronary artery disease; Endothelium dependent vasodilation; Metabolic syndrome; Remnant lipoproteins

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; INTERLEUKIN 6; LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ANGIOGRAPHY; ARTICLE; ATHEROGENESIS; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; HYPEREMIA; HYPERLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; VASOMOTOR DISORDER;

AGED; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; BEZAFIBRATE; BIOLOGICAL MARKERS; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PYRROLES; RISK FACTORS; TRIGLYCERIDES; VASODILATION;

EID: 22544446477     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.01.012     Document Type: Article

References (27)

1. S.M. Grundy, B. Hansen, S.C. Smith Jr., J.I. Cleeman, R.A. Kahn American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management Circulation 109 2004 551 556
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-97.
3. H.M. Lakka, D.E. Laaksonen, and T.A. Lakka The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2002 2709 2716
4. J.K. Ninomiya, G. L'Italien, and M.H. Criqui Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey Circulation 109 2004 42 46
5. M.P. Reilly, and D.J. Rader The metabolic syndrome: more than the sum of its parts? Circulation 108 2003 1546 1551
6. H.N. Ginsberg, and A.F. Stalenhoef The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk J Cardiovasc Risk 10 2003 121 128
7. E.A. Brinton Lipid abnormalities in the metabolic syndrome Curr Diab Rep 3 2003 65 72
8. K. Kugiyama, H. Doi, and T. Motoyama Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries Circulation 97 1998 2519 2526
9. K. Kugiyama, H. Doi, and K. Takazoe Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease Circulation 99 1999 2858 2860
10. H. Fukushima, K. Kugiyama, and S. Sugiyama Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease Am J Cardiol 88 2001 1370 1373
11. H. Fukushima, S. Sugiyama, and O. Honda Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus J Am Coll Cardiol 43 2004 2219 2224
12. H. Doi, K. Kugiyama, and H. Oka Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism Circulation 102 2000 670 676
13. H. Doi, K. Kugiyama, and M. Ohgushi Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation Atherosclerosis 137 1998 341 349
14. K. Nakajima, T. Saito, and A. Tamura Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels Clin Chim Acta 223 1993 53 71
15. P.C. Deedwania Mechanisms of endothelial dysfunction in the metabolic syndrome Curr Diab Rep 3 2003 289 292
16. J.H. Pinkney, C.D. Stehouwer, S.W. Coppack, and J.S. Yudkin Endothelial dysfunction: cause of the insulin resistance syndrome Diabetes 46 1997 S9 S13
17. The Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity New Criteria for 'Obesity Disease' in Japan Circ J 66 2002 987 992
18. K. Kugiyama, T. Motoyama, and H. Doi Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoproteins levels J Am Coll Cardiol 33 1999 1512 1518
19. T. Motoyama, H. Kawano, and K. Kugiyama Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina J Am Coll Cardiol 32 1998 1672 1679
20. A.S. Greenberg, R.P. Nordan, and J. McIntosh Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia Cancer Res 52 1992 4113 4116
21. K.R. Feingold, and C. Grunfeld Role of cytokines in inducing hyperlipidemia Diabetes 41 Suppl 2 1992 97 101
22. P.M. Ridker, J.E. Buring, N.R. Cook, and N. Rifai C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women Circulation 107 2003 391 397
23. A.R. Saniabadi, K. Umemura, and M. Shimoyama Aggregation of human blood platelets by remnant like lipoprotein particles of plasma chylomicrons and very low density lipoproteins Thromb Haemost 77 1997 996 1001
24. J. Malik, V. Melenovsky, and D. Wichterle Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT) Cardiovasc Res 52 2001 290 298
25. G. Paolisso, M. Barbagallo, and G. Petrella Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients Atherosclerosis 150 2000 121 127
26. I.J. Jonkers, M.F. Mohrschladt, R.G. Westendorp, A. van der Laarse, and A.H. Smelt Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial Am J Med 112 2002 275 280
27. M. Guerre-Millo, P. Gervois, and E. Raspe Peroxisome proliferator- activated receptor alpha activators improve insulin sensitivity and reduce adiposity J Biol Chem 275 2000 16638 16642